Summary: Genmab A/S announces its financial calendar for 2009.
Copenhagen, Denmark; December 10, 2008 - Genmab A/S (OMX: GEN) announces its
financial calendar for 2009 as follows:
--------------------------------------------------------------------------------
| EVENT | DATE |
--------------------------------------------------------------------------------
| Publication of the Financial Statement | Tuesday, February 24, 2009 |
| Release for 2008 | |
--------------------------------------------------------------------------------
| Publication of the Annual Report for 2008 | Tuesday, March 17, 2009 |
--------------------------------------------------------------------------------
| Annual General Meeting 2009 | Wednesday, April 15, 2009 |
--------------------------------------------------------------------------------
| Publication of the Interim Report for the | Tuesday, May 12, 2009 |
| first quarter 2009 | |
--------------------------------------------------------------------------------
| Publication of the Interim Report for the | Tuesday, August 18, 2009 |
| first half 2009 | |
--------------------------------------------------------------------------------
| Publication of the Interim Report for the | Tuesday, November 10, 2009 |
| first nine months 2009 | |
--------------------------------------------------------------------------------
Publication of the financial reports will be after market close on the date of
the event.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery, development and manufacturing teams are using
cutting-edge technology to create and develop products to address unmet medical
needs. Our primary goal is to improve the lives of patients who are in urgent
need of new treatment options. For more information on Genmab's products and
technology, visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. For a
further discussion of these risks, please refer to the section “Risk Management”
in Genmab's Annual Report, which is available on www.genmab.com. Genmab does
not undertake any obligation to update or revise forward looking statements in
this press release nor to confirm such statements in relation to actual results,
unless required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM)
and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Stock Exchange Release no. 56/2008
###
